#USA #Minneapolis #VentureMed Group #FLEX Vessel Prep #Bruce Fiedler

VentureMed Group Welcomes Bruce Fiedler as Chief Financial Officer

In a significant leadership announcement, VentureMed Group, Inc., a prominent medical device company focusing on vascular technology solutions, has appointed Bruce Fiedler as its new Chief Financial Officer (CFO). This strategic move is expected to drive the company’s financial operations and support its ongoing growth in developing innovative vascular interventions.

Bruce Fiedler joins VentureMed with a wealth of experience in financial leadership, having previously worked at Boston Scientific, where he served as Vice President of Finance and Global Controller for the Neuromodulation division. In that role, he oversaw financial planning and control for a major global business unit, showcasing his ability to manage complex financial landscapes effectively.

With a proven track record in driving operational performance within complex organizations, Fiedler will lead all financial efforts at VentureMed, including strategic planning, financial reporting, capital allocation, and investor relations. His extensive expertise in financial disciplines and a nuanced understanding of scaling operations in the medical technology industry will provide a significant advantage to the company as it navigates its next phase of growth.

Denis Harrington, the CEO of VentureMed Group, expressed enthusiasm about Fiedler joining the leadership team. He stated, “We are excited to welcome Bruce to the VentureMed Group leadership. His financial acumen and experience in scaling operations will be invaluable as we head into our next phase of growth. Bruce's strategic leadership will further strengthen our financial foundation and position us well to create long-term value.”

Fiedler's career reflects a commitment to operational excellence and financial discipline, marking him as a notable figure in the healthcare financial landscape. He has cultivated a reputation for fostering interdepartmental collaboration, which will be essential in aligning VentureMed's financial strategies with its growth objectives.

In expressing his commitment to the company, Fiedler commented, “I am thrilled to join the organization at this pivotal time. The company’s mission to address unmet clinical needs through innovative vascular solutions is compelling, and I look forward to partnering with the team to foster growth and have a meaningful impact on patients and physicians alike.”

About VentureMed Group

Founded in Minnesota, VentureMed Group is a private medical device pioneer dedicated to advancing endovascular solutions for arteriovenous access and peripheral vascular disease interventions. The company’s flagship technology, the FLEX Vessel Prep™ System, is FDA 510(k) cleared and CE-marked, designed to optimize vessel preparation through its proprietary Kinetic Endovascular Micro-incision Creation (KEMIC) technology. Unlike traditional balloon-based approaches that apply static pressure, KEMIC utilizes controlled motion and dynamic apposition of vessels to create long, precise micro-incisions, thereby enhancing procedural outcomes for clinicians and patients.

As the company continues to innovate and expand its reach in the medical field, the leadership of Bruce Fiedler is seen as a significant asset in ensuring that VentureMed Group stays at the forefront of vascular technology development and patient care improvements. For more information, visit VentureMed Group.